Print PDF

Sheppard Mullin Advises Cardiff Oncology, FoxWayne, Miva, And Others In Recent Deals


Sheppard Mullin’s Corporate practice has been busy closing a variety of deals and transactions over the past few months:


  • Represented Miva, Inc., a leading mid-market and enterprise ecommerce platform, in its equity investment from Boston-based growth equity firm Equality Asset Management.  The Sheppard Mullin deal team was led by partners Gemma Descoteaux and John Booher and included partners David Sands, Keith Gercken and Dmitriy Chelnitsky and associate Laura Baptista. (November 18)

Mergers & Acquisitions

  • Representing FoxWayne Enterprises Acquisition Corp. (NASDAQ: FOXWU), a special purpose acquisition company (SPAC), in its merger with Aerami Therapeutics Holdings, Inc., a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and chronic diseases. Upon closing, which is anticipated to occur in the first quarter of 2022, the combined company will be named “Aerami Therapeutics Holdings, Inc.” The Sheppard Mullin deal team is being led by partners Richard Friedman and John Hempill and includes several members of the firm’s Corporate and Securities practice across several offices, including partners Stephen Cohen, Kandace Watson, Dan Yannuzzi, Michael Chan, Allison Fulton, Keith Gercken, Dmitriy Chelnitsky, Shawn Fabian, Jamie Mercer, Olivier Theard, and Leo Caseria; special counsel Sean Reid; and associates Keren Baruch, Zach Norris, Nirav Bhatt, Karl Buhler, John Crisp, Brian Egan, Susan Ingargiola, Julia Kadish, Nazia Khan, Erica Kraus, Evan Lim, David Rostowsky, Elizabeth Rowe, Theresa Thompson, Michael Weisshar, and Hannah Zelcer; and attorney Wade Riachi. (December 7)
  • Represented Sia Partners, a leading international, independent management and AI consulting firm, in its acquisition of PPT Consulting, LLC, a privately held management and IT consulting firm that specializes in project management, business and process transformation, and organizational change management. The Sheppard Mullin deal team was led by partner Valerie Demont and associate Karl Buhler. Special assistance was provided by partners Michael Chan, Dmitriy Chelnitsky, Wynter Deagle, Niya Tang, and Dan Yannuzzi; special counsel Sean Kirby; and associates Evan Lim, Betsy Luxenberg, Deena Muzafar, and Michael Weisshar; and attorney Erin Hausladen. (December 7)

Public Offerings

  • Represented Immix Biopharma, Inc. (Nasdaq: IMMX), a biopharmaceutical company pioneering Tissue Specific Therapeutics targeting oncology and immuno-dysregulated diseases, in its initial public offering of $21 million. ThinkEquity is acting as the sole book-running manager for the offering. The Sheppard Mullin deal team included partner Jeff Fessler and associates Nazia Khan and Emily Mastoloni. (December 20)
  • Represented Merritt Island, Florida-based Sidus Space Inc. (NASDAQ:SIDU), in its $15 million initial public offering. Sidus Space is a Space-as-a-Service satellite company. The deal team was led by partner Jeff Fessler and special counsel Sean Reid. (December 13)
  • Advised Aditxt, Inc., a biotech innovation company with a mission to improve the health of the immune system, in a $17.4 million public offering.  The Sheppard Mullin deal team was led by partner Richard Friedman, special counsel Sean Reid and associate and Hannah Zelcer. (December 6)
  • Advised The Benchmark Company, LLC in connection with a public offering of Series A Cumulative Redeemable Perpetual Preferred Stock of Skylight Health Group, Inc., a healthcare services and technology company working to positively impact patient health outcomes, in a $5.8 million public offering.  The Sheppard Mullin deal team was led by partners Richard Friedman and Andrew Bond, special counsel Sean Reid, and associates Nazia Khan and Emily Mastoloni. (December 2)
  • Represented EF Hutton, a division of Benchmark Investments, LLC, in the private sale of securities of Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, for $30.4 million. The Sheppard Mullin team included partner Richard Friedman and associates Nazia Khan and Seth Lemings. (November 29)
  • Advised A. Davidson & Co. as sole placement agent in Summit Bank Group, Inc.’s $20 million private placement.  Summit Bank Group is the parent company of Summit Bank, which specializes in providing high-level service to professionals and medium-sized businesses and their owners. The deal team was led by partner Josh Dean and associate Eugene Choi. (November 23)
  • Represented Cardiff Oncology, a clinical-stage oncology company developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need, in Pfizer Inc.’s (NYSE: PFE) $15 million equity investment in the company as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs. The Sheppard Mullin team was led by partner Jeff Fessler. (November 18)
Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.